Weight loss pill revolution reveals business winners and losers
The UK approval in June of weight loss drug semaglutide in tablet form has accelerated one of the most remarkable mainstream medical trends in recent history; but what about the unintended consequences?
Given this is a business-focused website, we’re going to avoid analysis of vomiting, diarrhoea and constipation. Instead, TheBusinessDesk has asked around to find those sectors of the economy which are winning and losing off the back of the recent changes.
Before we get into it though, a quick explainer for those at the back.
Ozempic, a type two diabetes medication, and Wegovy, which is licensed for weight loss, both contain semaglutide, which mimics a naturally-occurring hormone: glucagon-like peptide-1 (GLP-1). These medications reduce the rate at which food is emptied from the stomach, suppress appetite and increase the production of insulin — hence their initial roll-out to treat diabetes. Mounjaro and Zepbound, meanwhile, contain the tirzepatide, which mimics both GLP-1 and another hormone.
Clinical trials suggest this class of drugs can help people lose an average of 15% to 20% of body weight, as well as helping with heart problems, fatty liver disease and addictions other than food.
YouGov’s latest quarterly research, among a nationally-representative sample of 2,000 British adults, revealed that approximately 8% have used GLP-1s and 14% would consider using them in the future.
Given the intended consequence of the medication is weight loss, the most obvious change is within what we eat and drink.
Those using them told YouGov about increasing intake of vegetables (38%), vitamins (23%) and seafood (21%) – suggesting a shift towards more nutrient-dense foods – while nearly two thirds (64%) ate fewer snacks, more than half (53%) reduced fast food consumption, as well as drinking less alcohol (39%) and fewer fizzy drinks (33%). They spent an average of £91 per week on household groceries, compared with £102 before starting treatment, while monthly takeaway spending fell from £49 to £30.
YouGov’s lead healthcare director Ag Hoffmann commented: “Whilst the number of users is relatively low at the moment, this is only going to increase in the future, creating both opportunities and threats to the wider market from quick-service retailers to grocers.”
Research from the Scotland Food & Drink Partnership confirmed that snacks are the biggest casualties in shoppers’ baskets, with more than three quarters (77%) spending less on cakes and biscuits, while four out of five (82%) have cut back on sweets and chocolate. Things like ready meals and ice cream also saw reduced reported spending, at 71% and 74% respectively. Alcohol sales are declining, while sales of no and low-alcohol products are on the rise, reflecting a wider market trend towards moderation.
A recent report from PwC suggested that changing the delivery method from injections to pills has already almost tripled penetration among UK adults, from 5% to 13%.
While not yet offered on the NHS, this shift is also leading to relative democratisation of the user profile, according to one of the report’s authors – and PwC UK’s head of retail – Jacqueline Windsor, who said it’s still “relatively younger and more affluent than the UK average”, but there is now more representation across all age and socio-demographic segments, including a quarter of users falling below the average UK household income.
“The pill format removes a big usage barrier, and generics are set to be introduced in the UK in 2031/32, which removes the price barrier,” she stated. “The future therefore is the consumerisation of health where GLP-1 is more than a medication; it will be a force of change that impacts the wider consumer economy where it will be normalised.”
PwC surveyed more than 2,300 UK adults and found that 80% of past users maintain at least some of their dietary changes after stopping. “The demand shift outlasts the prescription, which means category economics are being reset rather than dented,” the report read.
Windsor added that from her conversations, grocers have been first out of the block to respond, with things like smaller portion sizes and packaging specifying ‘high protein’ and ‘high fibre’ across many supermarkets. Marks & Spencer introduced a range of ‘nutrient dense’ food at the start of this year, while Ocado has created a weight management aisle on its website, and Itsu now offers ‘little’ options to cater to reduced appetites.

Taken from PwC’s Appetite for Disruption report
Leanne Crowther, co-founder of healthy snacking brand Flower & White, said: “For bakery and snacking, the emergence of GLP-1s means indulgence is not disappearing, but it is evolving – if people are eating less, they are less willing to waste an occasion on something average – that is particularly relevant in sweet bakery and snacking, where I think we’ll see more demand for products that feel special, but considered.
“For the wider industry, I see this as an opportunity rather than a threat, so brands that can combine enjoyment, transparency, convenience and better nutrition will be well placed as consumers become more selective about every bite.”
Dr Linia Patel, a registered dietitian and nutritionist at Pure Sports Medicine, said that GLP-1 medications have changed her day-to-day work enormously, as many are eating smaller portions and becoming more focused on nutrient density. “Eating substantially less can also mean skipping meals or falling short of protein, fibre and essential micronutrients because fullness arrives so quickly though, so we are already seeing increased purchases of protein powders and convenient, evidence-based products that deliver more nutritional value in smaller portions.
“The next major challenge – and commercial opportunity – is weight maintenance,” she continued, adding: “Many people are self-funding treatment and do not plan to remain on it indefinitely for various reasons, so if the time on medication is not used to establish supportive nutrition, movement and behavioural habits, the risk of weight regain after stopping is high.
“The businesses likely to succeed will be those that help people translate smaller portions and a renewed focus on health into sustainable habits during and after treatment — not those relying on quick fixes or exaggerated claims.”

Dietician and nutritionist Linia Patel
Its not just the supermarkets having to rethink though, as that Scotland Food & Drink Partnership research also found that 59% of those with experience of GLP-1 medications are eating out less, while almost half report spending more on clothing, as body size and shape have changed.
Research from Worldpanel by Numerator stated that 40% of those taking the drugs wanted to see smaller portion sizes on menus, while 26% requested a GLP-1-friendly section to choose from when eating out.
To combat a common side-effect – dry mouth and bad breath – many users have been buying more mouthwash and chewing gum, with sales up 20% and 24%, respectively, in GLP-1 user households compared with non-user households.
“For decades, huge parts of the consumer economy have been built around getting people to buy more, but GLP-1s potentially turn that model on its head,” commented Simon Betts, UK leader at shopper intelligence business Catalina. “It challenges some of the oldest tricks in the retail playbook – multi-buys, bigger packs and promotions are all designed to get more into the basket – retailers and brands will have to think differently about where growth comes from.
“The timing makes this particularly interesting,” he continued. “We’re heading into the ‘golden quarter’, when businesses traditionally rely on consumers spending more, entertaining more and indulging more.
“There will absolutely be winners as well as losers, as smaller portions, protein-rich products and different propositions create new opportunities – those that understand where spending is moving, rather than simply trying to recover lost volume, will be best placed to benefit.”
Windsor from PwC added that anecdotal announcements have been coming from different consumer categories addressing changes. “The likes of H&M, Mango and Zara are scaling back size curves, fitness operators like Equinox are offering tailored programmes and take-out operators are rethinking their menus; like Greggs’ Balanced Choice range.”
Elsewhere, wigmaker Banbury Postiche claims sales were up 20% year-on-year in the first quarter, with director Nick Allen opining that much of the extra demand came from people who’ve suffered hair loss after taking GLP-1.
“Consultant trichologists we work with report that up to a third of their female patients have recently been on a course of weight loss medication,” he shared. “Using GLP-1 essentially puts your body on a survival footing, prompting it to divert nutrients away from ‘non-essential’ parts of the body like hair.
“In some people, this causes the hair to thin or fall out, often in patches,” Allen went on. “Fortunately the baldness is usually temporary, but suddenly losing your hair can be very distressing for people; hence why some come to us.”

Ana Vilhete, co-founder of Themis Crown London
Sudden changes in appearance can also affect relationships.
Ana Vilhete, co-founder of law firm Themis Crown London, has witnessed a significant increase in people filing for divorce citing weight loss jabs in changing the dynamics of their marriage.
“This has been great for divorce lawyers, but obviously not great overall, as the breakdown of a marriage is never easy,” she said. “People who have been overweight all of their lives say that some of their partners have struggled to keep up with their new dieting plans, or handle the attention one receives from people who superficially overlooked them when they were heavier set.
“I have also worked with partners who were dumped by spouses who felt weight loss had given them clarity on issues they were unsure about.”
TheBusinessDesk has previously reported on how the rapid rise in use of GLP-1 led to a correlated fall in demand for weight-loss surgeries, with Cosmedicare chief executive Gill Baird explaining how her clinics were forced to pivot quickly into other areas.
“Injections really changed the game for bariatrics, so it’s been up and down over the last couple of years,” she commented at the end of last year. “As a result of our shift in strategy we’ve taken more market share from other procedures.”
William Van Nierkerk, consultant plastic surgeon at the Cadogan Clinic, said he’s been seeing a change in the types of patients consulting about abdominoplasty following substantial weight loss – with a growing number of men seeking surgery.
“Many people are reaching their target weight more rapidly and successfully – the downside, however, is that they can be left with significant quantities of loose, redundant skin, particularly around the abdomen.
“I believe men are becoming much more open about wanting to address this,” he continued. “Many of my male patients have worked incredibly hard to lose weight, making sustained changes to their diet and exercise, yet the residual skin can mean that their outward appearance does not reflect the scale of the transformation.”
Plastic surgeon Dr Marc Ronert, co-founder of IMAGE Skincare, agreed that rapid weight loss under GLP-1s has led to “accelerated volume loss and sagging, reduced density, dehydration and deeper wrinkles” in the face, while on the rest of the body “patients commonly experience laxity and a loss of firmness, particularly around the arms, abdomen and thighs, as the skin struggles to adapt to changes in body shape”.
He added: “This has led skincare to move beyond traditional anti-ageing concerns and develop more targeted solutions for people during and after significant weight loss.”
Meanwhile, Abbas Kanani, superintendent pharmacist of Chemist Click, said there’s more demand for advice around nausea, constipation, reflux, maintaining muscle mass, and getting enough protein, fibre and nutrients.
“Mounjaro also has specific implications for women taking the oral contraceptive pill around treatment initiation and dose increases, so these medicines are starting to influence areas of healthcare that people may not immediately associate with weight loss,” he stated.
“I think the biggest change is that obesity treatment is becoming much more long term – this is not just a short diet or a few months of treatment for many patients – as oral GLP-1 treatments make this type of medicine more accessible, the impact on consumer behaviour could become significant across food, hospitality, alcohol, nutrition and healthcare.”

Abbas Kanani, superintendent pharmacist of Chemist Click
Limited NHS availability of GLP-1s has pushed many people toward private providers, increasing risks of inadequate health monitoring and exacerbating inequalities in access to care.
Judit Mora, co-founder and chief executive of digital pharmacy platform Nuumad, pointed out that this is placing greater scrutiny on the digital systems through which patients access prescription medicines.
“Consumer technology has trained us to expect the shortest and easiest possible journey, but that principle cannot simply be transferred to healthcare – when someone is seeking a GLP-1 medicine, additional questions, checks or clinical reviews should not be treated as inconvenient friction to be designed out,” she said.
“There is a risk that commercial pressure encourages online providers to create highly persuasive or overly streamlined journeys – prioritising a particular treatment, minimising important information or making it easier to proceed than to pause and consider the risks.”
Adam Hunter, chief executive of healthtech business Phlo, recently told TheBusinessDesk that his team responded to the trend by launching a free app GLP-1 companion app to help patients with dose tracking and symptom management.
“I think GLP-1 is the most transformational drug since antibiotics and vaccines, in next five years it will be more common to be on some form of it than not,” Hunter opined. “There are plenty of studies about how it improves metabolic and cardiovascular health, helps with the heart, liver, kidneys, so I think people will get their own personal stack of peptides, following a diagnostic analysis.”
However, he added: “This is going to lead to a big discussion about accessibility for public health systems and how much budget the NHS can dedicate to something which could save money on admissions over the long-term, but will be expensive up-front.”




